|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Altekruse SF, McGlynn KA and Reichman ME:
Hepatocellular carcinoma incidence, mortality, and survival trends
in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bosetti C, Levi F, Boffetta P, Lucchini F,
Negri E and LaVecchia C: Trends in mortality from hepatocellular
carcinoma in Europe, 1980–2004. Hepatology. 48:137–145. 2008.
|
|
4
|
Adachi E, Maeda T, Matsumata T, et al:
Risk factors for intrahepatic recurrence in human small
hepatocellular carcinoma. Gastroenterology. 108:768–775. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kroncke KD, Fehsel K and Kolb-Bachofen V:
Inducible nitric oxide synthase in human diseases. Clin Exp
Immunol. 113:147–156. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thomsen LL, Miles DW, Happerfield L,
Bobrow LG, Knowles RG and Moncada S: Nitric oxide synthase activity
in human breast cancer. Br J Cancer. 72:41–44. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ambs S, Merriam WG, Bennett WP, et al:
Frequent nitric oxide synthase-2 expression in human colon
adenomas: implication for tumor angiogenesis and colon cancer
progression. Cancer Res. 58:334–341. 1998.PubMed/NCBI
|
|
8
|
Ekmekcioglu S, Ellerhorst J, Smid CM, et
al: Inducible nitric oxide synthase and nitrotyrosine in human
metastatic melanoma tumors correlate with poor survival. Clin
Cancer Res. 6:4768–4775. 2000.PubMed/NCBI
|
|
9
|
Masri FA, Comhair SA, Koeck T, et al:
Abnormalities in nitric oxide and its derivatives in lung cancer.
Am J Respir Crit Care Med. 172:597–605. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huerta S, Chilka S and Bonavida B: Nitric
oxide donors: novel cancer therapeutics (Review). Int J Oncol.
33:909–927. 2008.PubMed/NCBI
|
|
11
|
Shaulsky G, Goldfinger N and Rotter V:
Alterations in tumor development in vivo mediated by expression of
wild type or mutant p53 proteins. Cancer Res. 51:5232–5237.
1991.PubMed/NCBI
|
|
12
|
Bonavida B and Baritaki S: Dual role of NO
donors in the reversal of tumor cell resistance and EMT:
downregulation of the NF-kB/Snail/YY1/RKIP circuitry. Nitric Oxide.
24:1–7. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hickok JR, Sahni S, Mikhed Y, Bonini MG
and Thomas DD: Nitric oxide suppresses tumor cell migration through
N-Myc downstream-regulated gene-1 (NDRG1) expression: role of
chelatable iron. J Biol Chem. 286:41413–41424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bonavida B, Baritaki S, Huerta-Yepez S,
Vega MI, Chatterjee D and Yeung K: Novel therapeutic applications
of nitric oxide donors in cancer: roles in chemo- and
immunosensitization to apoptosis and inhibition of metastases.
Nitric Oxide. 19:152–157. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hussain SP, Trivers GE, Hofseth LJ, et al:
Nitric oxide, a mediator of inflammation, suppresses tumorigenesis.
Cancer Res. 64:6849–6853. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Le X, Wei D, Huang S, Lancaster JR Jr and
Xie K: Nitric oxide synthase II suppresses the growth and
metastasis of human cancer regardless of its up-regulation of
protumor factors. Proc Natl Acad Sci USA. 102:8758–8763. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thilakawardhana S, Everett DM, Murdock PR,
Dingwall C and Owen JS: Quantification of apolipoprotein E
receptors in human brain-derived cell lines by real-time polymerase
chain reaction. Neurobiol Aging. 26:813–823. 2005. View Article : Google Scholar
|
|
18
|
Yang XR, Xu Y, Yu B, et al: CD24 is a
novel predictor for poor prognosis of hepatocellular carcinoma
after surgery. Clin Cancer Res. 15:5518–5527. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rahman MA, Dhar DK, Yamaguchi E, et al:
Coexpression of inducible nitric oxide synthase and COX-2 in
hepatocellular carcinoma and surrounding liver: possible
involvement of COX-2 in the angiogenesis of hepatitis C
virus-positive cases. Clin Cancer Res. 7:1325–1332. 2001.
|
|
20
|
Wei D, Richardson EL, Zhu K, et al: Direct
demonstration of negative regulation of tumor growth and metastasis
by host-inducible nitric oxide synthase. Cancer Res. 63:3855–3859.
2003.PubMed/NCBI
|
|
21
|
Sugita H, Kaneki M, Furuhashi S, Hirota M,
Takamori H and Baba H: Nitric oxide inhibits the proliferation and
invasion of pancreatic cancer cells through degradation of insulin
receptor substrate-1 protein. Mol Cancer Res. 8:1152–1163. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bossi G, Lapi E, Strano S, Rinaldo C,
Blandino G and Sacchi A: Mutant p53 gain of function: reduction of
tumor malignancy of human cancer cell lines through abrogation of
mutant p53 expression. Oncogene. 25:304–309. 2006.PubMed/NCBI
|
